SIRs for non-germinal center neoplasms in autoimmune disease patients.

<p>SIRs for non-germinal center neoplasms in autoimmune disease patients.</p

SIR for non-germinal center neoplasms in autoimmune disease patients.

<p>Red bars show significant and blue bars not significant associations.</p

SIRs for primarily germinal center-derived neoplasms in autoimmune disease patients.

<p>Red bars show significant and blue bars not significant associations.</p

Odds ratios (ORs) for TNM classes in postmenopausal lobular carcinoma by reproductive factors.

<p>Bold type: 95% CI does not include 1.00. The ORs were adjusted for:</p><p>1. Age at diagnosis, region, and occupation.</p><p>2. Age at diagnosis, region, occupation, and parity.</p>*<p>Carcinoma in situ.</p>**<p>The number of cases for T2 (N = 1,106), T3 (236), and T4 (75).</p

Odds ratios (ORs) for TNM classes in premenopausal ductal carcinoma by reproductive factors.

<p>Bold type: 95% CI does not include 1.00. The ORs were adjusted for:</p><p>1. Age at diagnosis, region, and occupation.</p><p>2. Age at diagnosis, region, occupation, and parity.</p>*<p>Carcinoma in situ.</p>**<p>The number of cases for T2 (N = 1,047), T3 (176), and T4 (65).</p

Odds ratios (ORs) for TNM classes in postmenopausal breast cancer by age at first and last childbirth, stratified by time interval between first and last childbirth.

<p>Bold type: 95% CI does not include 1.00.</p><p>Women with two or more children were included. ORs were adjusted for parity, region and occupation.</p>*<p>Carcinoma in situ.</p

Odds ratios (ORs) for TNM classes in postmenopausal breast cancer by reproductive factors.

<p>Bold type: 95% CI does not include 1.00. The ORs were adjusted for:</p><p>1. Age at diagnosis, region, and occupation.</p><p>2. Age at diagnosis, region, occupation, and parity.</p>*<p>Carcinoma in situ.</p>**<p>The number of cases for T2 (N = 6,098), T3 (871), and T4 (654).</p

An example of the fragment analysis results using the GeneMapper 4 software

<p><b>Copyright information:</b></p><p>Taken from "High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk"</p><p>http://www.biomedcentral.com/1471-2156/8/41</p><p>BMC Genetics 2007;8():41-41.</p><p>Published online 29 Jun 2007</p><p>PMCID:PMC1925117.</p><p></p> (A) A homozygous sample for the wild type allele, 186 bp. (B) A homozygous sample for the deletion allele, 301 bp. (C) A heterozygous samples, 186 bp + 301 bp

(A) Schematic diagram of the deletion and the location of the primers used for fluorescent fragment analysis

<p><b>Copyright information:</b></p><p>Taken from "High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk"</p><p>http://www.biomedcentral.com/1471-2156/8/41</p><p>BMC Genetics 2007;8():41-41.</p><p>Published online 29 Jun 2007</p><p>PMCID:PMC1925117.</p><p></p> (B) PCR products amplified by multiplex PCR. (C) PCR products created for fluorescent fragment analysis by SchI digestion

DC-SIGN and Dectin-1 polymorphisms associated with susceptibility to Invasive Pulmonary Aspergillosis.

1<p>Models adjusted for age, gender, hematological malignancy, HSCT, neutropenia (defined as absolute neutrophil count <500 cells/mm3 for a period of more than 10 days), GVHD and corticoid therapy use (>0.3 mg/Kg/day).</p>‡<p>Assuming a recessive model of inheritance. Abbreviations: OR, odds ratio; CI, confidence interval. Differences in samples numbers are due to failures in genotyping.</p